Advanced Prostate Cancer VL

Understanding BRCA Mutations: The Pivotal Impact of the CAPTURE Study - David Olmos

Details
In a conversation between Alicia Morgans and David Olmos, they discussed the exciting findings from Olmos' presentation focusing on prostate cancer patients with BRCA mutations. Dr. Olmos highlighted that BRCA1 and BRCA2 mutation patients, regardless of germline or somatic origin, generally have worse outcomes compared to other patients. The CAPTURE study he spearheaded, which involved multiple co...

The Added Value of Docetaxel in Combination with ADT and ARPI for the Treatment of mHSPC - Ursula Vogl

Details
Ursula Vogl converses with Alicia Morgans about determining optimal therapeutic strategies in treating metastatic hormone-sensitive prostate cancer. Vogl discusses the selection between doublet and triplet therapies, acknowledging that there are no absolute answers. She presents her pro-triplet therapy argument from the European Association of Urology (EAU) 2023 meeting. Referencing key trials suc...

Navigating Salvage Radiotherapy with Insights from PSMA PET - Jeremie Calais

Details
Jeremie Calais discusses a retrospective analysis of the use of PSMA PET in salvage radiotherapy with Alicia Morgans. The study focused on the application of PSMA PET findings to the treatment of patients with biochemical recurrence after radical prostatectomy, with approximately 4-5 years of follow-up. They discovered that disease presence correlates with negative outcomes and that the number of...

Predictive Modeling for 177Lu-PSMA-617 Therapy in Patients with mCRPC - Ken Herrmann

Details
Phillip Koo interviews Ken Herrmann about his presentation focusing on a predictive model for 177Lu-PSMA-617. Herrmann explains the difference between a prognostic tool, which indicates a patient's overall prognosis, and a predictive tool that specifies whether a patient is likely to benefit from a particular therapy. He presents a model based on data from the Vision trial and explains how this mo...

Unlocking Prostate Cancer Treatment: The Pathway of CAR T Targeting Prostate Stem Cell Antigen - Tanya Dorff

Details
Tanya Dorff shares her team’s insights on research into CAR T therapy targeting Prostate Stem Cell Antigen (PSCA). Their analysis shows promise in managing advanced castration-resistant prostate cancer. However, this treatment also presents challenges, including the issue of dose escalation due to the occurrence of high-grade cystitis, a complication encountered during the trials. In response, Dor...

Integration of Lutetium into Clinical Practice: A Urologist's Perspective - Neal Shore

Details
Alicia Morgans and Neal Shore discuss the integration of the newly-approved Lutetium-617 into clinical practice for the treatment of advanced prostate cancer. The conversation revolves around the revolutionary potential of theranostics, where radiopharmaceuticals are linked with antibodies, such as PSMA. They further analyze the VISION trial, which demonstrated survival and quality of life benefit...

Beyond BRCA-1 and 2: The Impact of the TALAPRO-2 Study on Prostate Cancer Care - Cora Sternberg

Details
Alicia Morgans speaks with Cora Sternberg about precision medicine's transformative impact on prostate cancer treatment. A key topic is the TALAPRO-2 study, which examines the efficacy of the PARP inhibitor talazoparib in combination with enzalutamide in treating metastatic castration-resistant prostate cancer (CRPC). The study's positive findings suggest significant benefits for patients with BRC...

Navigating the Future of Prostate Cancer Treatment and Global Access at APCCC 2024 - Silke Gillessen

Details
Alicia Morgans engages with Silke Gillessen to discuss the upcoming APCCC conference in 2024. The conference seeks to address some of the major questions in clinical practice such as the management of biochemical relapse after radical prostatectomy and the application of novel endocrine agents plus PARP inhibitors in first line mCRPC treatments. Side effects and their management, especially those...

Beyond Medical Advancements: Addressing Financial and Personal Challenges in Metastatic Castration-Sensitive Prostate Cancer Treatment - Neeraj Agarwal

Details
Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers. Primaril...

Combating Prostate Cancer: The Role of the NRG-GU-011 Study in Transforming Treatments - Bridget Koontz

Details
Alicia Morgans engages in a conversation with Bridget Koontz about the NRG-GU-011 (NRG PROMETHEAN) study. This double-blinded, randomized phase II trial focuses on prostate cancer patients with biochemical recurrence and oligometastatic disease, detected via PET scan. The study explores the potential benefits of radiation, specifically SBRT, either alone or combined with Relugolix for six months....